Yama F Mujadidi

BCA Computer Application , MSc in Information Technology and Software Engineering

Clinical Trials IT and Development Lead

Yama F Mujadidi has expertise in the design and development of software and is currently working with Oxford Vaccine Group in the capacity of Clinical Trials IT and Development Lead. He acquired an MSc in Information Technology from University of Bradford United Kingdom, in 2012 after he earned a First class degree in BCA Computer Application from the University of Pune, in the year 2010.
Yama joined Oxford Vaccine Group in June 2013 and tasked to provide specialist advice to research groups to improve quality of clinical trials and to develop an application based on the vaccine knowledge project for use in smart-phones/tablets. Before Oxford Vaccine Group, He had been working with Omni Communication Product Limited as a software developer and contributed to the development of a multi-communication application for use in smartphones and tablets.

Recent publications

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Journal article

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trial
Journal article

Clemens SC. et al, (2021)
Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine
Journal article

Liu X. et al, (2021), SSRN Electronic Journal
Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)
Journal article

Flaxman A. et al, (2021), SSRN Electronic Journal
T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.
Journal article

Swanson PA. et al, (2021), medRxiv
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Journal article

Frater J. et al, (2021), Lancet HIV
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article

Ewer KJ. et al, (2021), Nat Med
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Journal article

Shaw RH. et al, (2021), Lancet
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article

Barrett JR. et al, (2021), Nat Med
Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection
Journal article

Frater J. et al, (2021), SSRN Electronic Journal
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Journal article

Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
Journal article

Madhi SA. et al, (2021), N Engl J Med
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article

Voysey M. et al, (2021), Lancet, 397, 881 - 891
Successful incorporation of a genetic risk prediction research platform into routine newborn screening
Journal article

Bendor-Samuel OM. et al, (2021)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)
Journal article

Emary KRW. et al, (2021), SSRN Electronic Journal
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
Journal article

Voysey M. et al, (2021), SSRN Electronic Journal
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article

Barrett JR. et al, (2021), Nat Med, 27, 279 - 288
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article

Ewer KJ. et al, (2021), Nat Med, 27, 270 - 278
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Journal article

Voysey M. et al, (2021), Lancet, 397, 99 - 111
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)
Internet publication

Folegatti PM. et al, (2020), 396, 1884 - 1884
Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia
Journal article

Thindwa D. et al, (2020), Wellcome Open Research, 5, 66 - 66
Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model.
Journal article

Gibani MM. et al, (2020), PLoS Negl Trop Dis, 14
Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia.
Journal article

Thindwa D. et al, (2020), Wellcome open research, 5, 66 - 66
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Journal article

Folegatti PM. et al, (2020), Lancet, 396, 467 - 478
Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants.
Internet publication

Valente Pinto M. et al, (2020), 7
Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia.
Journal article

Thindwa D. et al, (2020), Wellcome Open Res, 5
Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
Journal article

Shakya M. et al, (2019), N Engl J Med, 381, 2209 - 2218
Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials-GPPAD-02 study design and first results.
Journal article

Winkler C. et al, (2019), Pediatr Diabetes, 20, 720 - 727
Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial.
Journal article

Theiss-Nyland K. et al, (2019), Clin Infect Dis, 68, S74 - S82
Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.
Journal article

Theiss-Nyland K. et al, (2019), Clin Infect Dis, 68, S67 - S73

More publications